These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7737227)

  • 1. Rapid intravenous infusion of d-1 sotalol: time to onset of effects on ventricular refractoriness, and safety.
    Ho DS; Zecchin RP; Cooper MJ; Richards DA; Uther JB; Ross DL
    Eur Heart J; 1995 Jan; 16(1):81-6. PubMed ID: 7737227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
    Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
    Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiarrhythmic effects of d-sotalol.
    Schwartz J; Crocker K; Wynn J; Somberg JC
    Am Heart J; 1987 Sep; 114(3):539-44. PubMed ID: 3630894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
    Trappe HJ; Klein H; Lichtlen PR
    Z Kardiol; 1987 Oct; 76(10):630-4. PubMed ID: 3687165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
    Kehoe RF; Zheutlin TA; Dunnington CS; Mattioni TA; Yu G; Spangenberg RB
    Am J Cardiol; 1990 Jan; 65(2):58A-64A; discussion 65A-66A. PubMed ID: 2294689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
    Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
    Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
    Jordaens LJ; Palmer A; Clement DL
    Eur Heart J; 1989 Mar; 10(3):218-26. PubMed ID: 2707270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
    Wehr M
    Z Kardiol; 1986 Dec; 75(12):744-50. PubMed ID: 3825224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
    Singh SN; Cohen A; Chen YW; Wish M; Thoben-O'Grady L; Peralba J; Gottdiener J; Fletcher RD
    Am J Cardiol; 1988 Sep; 62(7):399-402. PubMed ID: 2458026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
    Brachmann J; Senges J; Lengfelder W; Jauernig R; Rizos I; Czygan E; Cobbe SM; Kübler W
    Eur Heart J; 1985 Nov; 6 Suppl D():171-4. PubMed ID: 3936715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
    Kühlkamp V; Mermi J; Mewis C; Braun U; Seipel L
    Eur Heart J; 1995 Nov; 16(11):1625-31. PubMed ID: 8881857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of sotalol and procainamide in symptomatic ventricular tachycardia.
    Jordaens LJ; Colardyn F; Clement DL
    Cardiovasc Drugs Ther; 1989 Apr; 3(2):155-61. PubMed ID: 2487531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease.
    Miyazaki A; Ohuchi H; Kurosaki K; Kamakura S; Yagihara T; Yamada O
    Circ J; 2008 Dec; 72(12):1998-2003. PubMed ID: 18931451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy.
    Dorian P; Newman D; Sheahan R; Tang A; Green M; Mitchell J
    J Cardiovasc Electrophysiol; 1996 Oct; 7(10):952-61. PubMed ID: 8894937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia.
    Morady F; Kou WH; Kadish AH; Nelson SD; Toivonen LK; Kushner JA; Schmaltz S; de Buitleir M
    J Am Coll Cardiol; 1988 Aug; 12(2):388-94. PubMed ID: 3392332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does sotalol have reverse-use dependence during tachyarrhythmias?
    Kovoor P; Byth K; Uther JB; Ross DL
    Am J Cardiol; 1996 Jul; 78(2):247-50. PubMed ID: 8712156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia.
    Ho DS; Zecchin RP; Richards DA; Uther JB; Ross DL
    Lancet; 1994 Jul; 344(8914):18-23. PubMed ID: 7912296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease.
    Winters SL; Kukin M; Pe E; Stewart D; Deitchman D; Gomes JA
    Am J Cardiol; 1993 Aug; 72(4):38A-43A. PubMed ID: 8346725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Electrophysiologic effect of sotalol in supraventricular tachycardias].
    Borggrefe M; Breithardt G
    Z Kardiol; 1985 Sep; 74(9):506-11. PubMed ID: 4060828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.